Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Cash from Operations came in at 3366000.0 in Q1 2026, up 77.41% YoY from 1897274.08 in Q1 2025, and up 20.65% on a QoQ basis from 4242000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Cash from Operations (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Cash from Operations data on file, last reported at 3366000.0 in Q1 2026.
- Quarterly Cash from Operations rose 77.41% year-over-year to 3366000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36443000.0 (down 13.81% YoY) and the FY2025 annual result came in at 47979000.0, down 65.79% from the prior year.
- Cash from Operations grew to 3366000.0 in Q1 2026, from 4242000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 13086000.0 in Q4 2024 to a low of 19603000.0 in Q4 2023.
- A 5-year average of 8567117.65 and a median of 11191000.0 in 2023 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 688.9% — and 2024, when it sank 272.46%.
- Tracing BRNS's Cash from Operations over 5 years: stood at 11343000.0 in 2022, then sank by 72.82% to 19603000.0 in 2023, then surged by 166.76% to 13086000.0 in 2024, then slumped by 132.42% to 4242000.0 in 2025, then gained by 20.65% to 3366000.0 in 2026.
- The last three Cash from Operations figures came in at 3366000.0 (Q1 2026), 4242000.0 (Q4 2025), and 10726000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -8.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.09 Mn |
| Jun 30, 2026 | -8.09 Mn |
| Mar 31, 2026 | -3.37 Mn |
| Mar 31, 2026 | -3.37 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Dec 31, 2025 | -4.24 Mn |
| Sep 30, 2025 | -10.73 Mn |
| Sep 30, 2025 | -10.73 Mn |
| Jun 30, 2025 | -18.11 Mn |
| Jun 30, 2025 | -18.11 Mn |
| Mar 31, 2025 | -14.90 Mn |
| Mar 31, 2025 | -14.90 Mn |
| Dec 31, 2024 | 13.09 Mn |
| Dec 31, 2024 | 13.09 Mn |
| Sep 30, 2024 | -18.20 Mn |
| Sep 30, 2024 | -18.20 Mn |
| Jun 30, 2024 | -12.01 Mn |
| Jun 30, 2024 | -12.01 Mn |
| Mar 31, 2024 | -11.82 Mn |
| Mar 31, 2024 | -11.82 Mn |